A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal.
about
Targeting gastrointestinal stromal tumors: the role of regorafenibCIViC databasePI3K and cancer: lessons, challenges and opportunitiesCharacterization and assessment of the sensitivity and resistance of a newly established human gastrointestinal stromal tumour xenograft model to treatment with tyrosine kinase inhibitors.Pazopanib, a Receptor Tyrosine Kinase Inhibitor, Suppresses Tumor Growth through Angiogenesis in Dedifferentiated Liposarcoma Xenograft ModelsTherapeutic Efficacy Assessment of CK6, a Monoclonal KIT Antibody, in a Panel of Gastrointestinal Stromal Tumor Xenograft Models.Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor.Expression profiling of receptor tyrosine kinases in high-grade neuroendocrine carcinoma of the lung: a comparative analysis with adenocarcinoma and squamous cell carcinomaKIT over-expression by p55PIK-PI3K leads to Imatinib-resistance in patients with gastrointestinal stromal tumorsSuccessful establishment of patient-derived tumor xenografts from gastrointestinal stromal tumor-a single center experienceUpdate on imatinib for gastrointestinal stromal tumors: duration of treatment.Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics.Recent advances in the treatment of gastrointestinal stromal tumors.Prognostic impact of gastrointestinal bleeding and expression of PTEN and Ki-67 on primary gastrointestinal stromal tumors.The DREAM complex in antitumor activity of imatinib mesylate in gastrointestinal stromal tumors.PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors.Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma.Frequent mono-allelic loss associated with deficient PTEN expression in imatinib-resistant gastrointestinal stromal tumors.microRNA-218 increase the sensitivity of gastrointestinal stromal tumor to imatinib through PI3K/AKT pathway.Evolutionary scalpels for dissecting tumor ecosystems.Frequency and clinicopathologic profile of PIK3CA mutant GISTs: molecular genetic study of 529 cases.Evaluating new therapies in gastrointestinal stromal tumor using in vivo molecular optical imagingCowden syndrome complicated by a gastrointestinal stromal tumor.New targets and therapies for gastrointestinal stromal tumors.Direct engagement of the PI3K pathway by mutant KIT dominates oncogenic signaling in gastrointestinal stromal tumor.Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor.Comprehensive analysis of T cell leukemia signals reveals heterogeneity in the PI3 kinase-Akt pathway and limitations of PI3 kinase inhibitors as monotherapy.
P2860
Q26747162-B8AFE1E0-72AA-485D-8BA1-77A5259CA1A7Q27612411-6D3910AE-7C8B-48EA-A217-779C788A2FD6Q30080017-A4B33171-BF15-4E71-8292-DA5BF1837222Q34052411-8579E4E2-FFE9-4B83-8CA9-DDFD2451B210Q35028802-6FBC0478-6B8B-4556-BA5D-2553F55C2288Q35555471-1E87BB67-7BFE-4085-8FCB-49E5172D306BQ36125976-CE370F43-B6B6-4CE7-9D40-211BA7563B61Q36240984-0902A9BD-8F83-40A5-A31A-A15E40334B59Q36738831-6F985DF2-00C4-40D4-A1C0-CBCF426D389AQ36874692-A039434E-0683-4C5E-803D-47E09E2C8F53Q37075052-5803AD0A-F13B-4186-8466-F2E775CCDABCQ37350230-0DBCEE06-C277-436B-80FA-8CED6D639C5FQ37704347-12C617B4-F5DF-418A-AC44-597A89C1410EQ37710557-8E06D2C5-C20F-4EE4-BA55-0381FC5CB23DQ38212772-ACDF44FB-68C3-4CFD-B012-E2EA4E71E36AQ38775158-C987A649-5A13-4B14-BC35-73E552548026Q38927569-C930743A-4FF0-4072-A722-6B94B0822400Q39003171-869D7952-3C9C-4F3A-88ED-073D9CFAA0C7Q39007220-1E0495DF-4B43-462A-BDC6-5DCBDFB9C592Q39030938-BED74EA5-9550-4001-847A-021E746F3F58Q40076921-D3A6CF0D-7705-4F5C-81C3-19755E0F5F77Q41963175-491B84FF-E66B-4BFB-A17F-783BB93915A0Q45088294-B587C43D-AE7B-4728-9E6D-23A5D5990FDCQ47432725-10A28E63-5720-4079-9637-DC049870C753Q48327749-5C0DB6AE-ED70-4691-BD56-0B27ACDD0630Q48644058-F690BB49-5DF7-4BB1-9CF7-0A8AC6143B0CQ54978251-72E8CBD9-321D-44D9-A1FB-28B18B916125
P2860
A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal.
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
A potent combination of the no ...... es after treatment withdrawal.
@ast
A potent combination of the no ...... es after treatment withdrawal.
@en
A potent combination of the no ...... es after treatment withdrawal.
@nl
type
label
A potent combination of the no ...... es after treatment withdrawal.
@ast
A potent combination of the no ...... es after treatment withdrawal.
@en
A potent combination of the no ...... es after treatment withdrawal.
@nl
altLabel
A Potent Combination of the No ...... ses after Treatment Withdrawal
@en
prefLabel
A potent combination of the no ...... es after treatment withdrawal.
@ast
A potent combination of the no ...... es after treatment withdrawal.
@en
A potent combination of the no ...... es after treatment withdrawal.
@nl
P2093
P2860
P50
P3181
P1476
A potent combination of the no ...... es after treatment withdrawal.
@en
P2093
Christophe M Deroose
Jonathan A Fletcher
Lori Friedman
Peter Vermaelen
Thomas Van Looy
P2860
P304
P3181
P356
10.1158/1078-0432.CCR-12-2853
P407
P577
2013-02-01T00:00:00Z